Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2L5186303 is an LPA2 antagonist and can be used in studies about asthma treatment.
説明 | H2L5186303 is an LPA2 antagonist and can be used in studies about asthma treatment. |
ターゲット&IC50 | LPA2 receptor:9 nM (IC50) |
In vitro | The high cell invasion activity of HT1080-M6 cells is significantly suppressed by H2L5186303[1]. |
In vivo | H2L5186303 shows strong suppressive efficacy when administered before OVA sensitization and challenge, such as suppression of airway hyper responsiveness, inflammatory cytokine levels, mucin production, and eosinophil numbers[2]. |
別名 | ZINC33388081 |
分子量 | 488.45 |
分子式 | C26H20N2O8 |
CAS No. | 139262-76-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200 mg/mL (409.5 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
H2L5186303 139262-76-3 GPCR/G Protein LPA Receptor H2L-5186303 ZINC-33388081 H2L 5186303 ZINC33388081 ZINC 33388081 Inhibitor inhibitor inhibit